Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy men and women, ages 18 to 49 yr old * BMI 18 to 32 * Women must not be pregnant or breastfeeding Exclusion Criteria: * Any significant acute or chronic medical illness * A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) * History of hypokalemia, personal history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age * History of biliary disorders, including Gilbert's disease or Dubin-Johnson disease * Inability to swallow multiple tablets consecutively * Any of the following on 12-lead electrocardiogram (ECG) prior to study drug administration: PR ≥ 210 msec, QRS ≥ 120 msec, QT ≥ 500 msec, QTcF ≥ 450 msec, Heart Rate (HR) \< 45 bpm * Second or third degree heart block prior to study drug * Positive urine screen for drugs of abuse * Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV)-1, -2 antibody * Any of the following lab results outside of the ranges specified below prior to dosing: Alanine aminotransferase (ALT) \> upper limit of normal (ULN), Aspartate aminotransferase (AST) \> ULN, Total bilirubin \> ULN, Direct bilirubin \> ULN, Creatinine \> ULN, Serum potassium \< lower limit of normal (LLN), Serum magnesium \< LLN * History of allergy to Moxifloxacin, BMS-791325, nonstructural protein 5B (NS5B) non-nucleoside inhibitors or related compounds